BACKGROUND & AIMS The lack of a preclinical model of progressive non-alcoholic steatohepatitis (NASH) that recapitulates human disease is a barrier to therapeutic development. METHODS A stable isogenic cross between C57BL/6J (B6) and 129S1/SvImJ (S129) mice were fed a high fat diet with ad libitum consumption of glucose and fructose in physiologically relevant concentrations and compared to m...

Nonalcoholic fatty liver disease is a clinicopathologic syndrome that encompasses several clinical entities. The spectrum of conditions ranges from simple steatosis to steatohepatitis, fibrosis and end stage liver disease. The condition was originally described in obese, diabetic, middle-aged females without a history of significant alcohol use with liver histology consistent with alcoholic hep...

Reactive oxygen species (ROS) play a significant role in the survival and decline of various biological systems. In liver-related metabolic disorders such as steatohepatitis, ROS can act both cause consequence. Alcoholic steatohepatitis (ASH) non-alcoholic (NASH) are two distinct types steatohepatitis. Recently, there has been growing interest using medications that target formation reduce leve...

Non-alcoholic fatty liver disease (NAFLD) is a major cause of worldwide, affecting up to 30% adults. Progression non-alcoholic steatohepatitis (NASH) key risk factor for cirrhosis, hepatocellular carcinoma and cardiovascular events. Alterations in reproductive hormones are linked the development and/or progression NAFLD/NASH women. Women with Polycystic Ovary Syndrome (PCOS) those estrogen defi...

Non-alcoholic steatohepatitis (NASH) is a clinicopathological entity characterized by histological features resembling alcoholic liver disease that occurs in persons who consume little or no alcohol. NASH is a part of the spectrum of non-alcoholic fatty liver disease (NAFLD) and is defined by of the presence of ballooning (zone 3) hepatocellular injury and inflammation in addition to steatosis....

The retrospective analysis of 378 medical records inpatients with steatohepatitis (SH) depending on its etiology was performed to identify and study the type anaemic conditions (AC). Among patients SH mixed (including alcoholic) anaemia found in 32.2% cases, alcoholic (ASH) - 36.3%, non-alcoholic (NASH) 22.0 % cases. Macrocytic, hyperchromic prevailed all groups: 47.9%, ASH 56.8%, NASH 71.4%. N...

Background The prevalence of obesity in children increased from year to year and cause a variety of chronic diseases such as Non Alcoholic Steatohepatitis (NASH). NASH is a liver inflammation due to accumulation of fat in the liver, which had no relationship with alcohol consumption, but associated with obesity and diabetes factors. In most cases, diagnosis of NASH was established by elevated l...

CONTEXT Nonalcoholic Fatty Liver Disease (NAFLD) is the major chronic liver disease in the pediatric population. NAFLD includes a broad spectrum of abnormalities (inflammation, fibrosis and cirrhosis), ranging from accumulation of fat (also known as steatosis) towards non-alcoholic steatohepatitis (NASH). The development of NAFLD in children is significantly increased. EVIDENCE ACQUISITION A ...

Although obesity is undoubtedly major risk for non-alcoholic steatohepatitis (NASH), the presence of lean NASH patients with normal body mass index has been recognized. Here, we report that the insufficiency of phosphatidylethanolamine N-methyltransferase (PEMT) is a risk for the lean NASH. The Pemt-/- mice fed high fat-high sucrose (HFHS) diet were protected from diet-induced obesity and diabe...

Objective(s):Non-alcoholic steatohepatitis (NASH), is an important component of Non-alcoholic fatty liver disease (NAFLD) spectrum, which progresses to the end stage liver disease, if not diagnosed and treated properly. The disproportionate production of pro- and anti-inflammatory adipokines secreted from fat contributes to the pathogenesis of NASH. In this study, the comparative effect of piog...